From GlobeNewswire: 2025-02-14 17:27:19

The FDA has approved VIMKUNYA, the first chikungunya vaccine for individuals aged 12 and older, with a commercial launch in the U.S. planned for the first half of 2025. The vaccine demonstrated a high rate of neutralizing antibodies and rapid immune response in clinical trials. Chikungunya, a mosquito-borne disease, has caused over 620,000 cases and 200 deaths globally in 2024, with underreporting common. VIMKUNYA is a single-dose vaccine supplied in a pre-filled syringe. Safety information and side effects were also disclosed. Bavarian Nordic aims to provide the vaccine in European markets as well pending approval.



Read more at GlobeNewswire: Bavarian Nordic Receives U.S. FDA Approval of Chikungunya